Wala Elzbieta P, Sloan Paul A, Holtman Joseph R
Department of Anesthesiology, College of Medicine, University of Kentucky, Lexington, USA.
J Opioid Manag. 2011 Sep-Oct;7(5):377-89. doi: 10.5055/jom.2010.0079.
In addition to producing analgesia, opioids can increase sensitivity to pain (opioid-induced hyperalgesia [OIH]) in humans and rodents. Tolerance/OIH is likely mediated by similar mechanisms that lead to development of hyperalgesia after nerve injury (neuropathic pain). OIH may be a reason for loss of opioid efficacy and/or a worsening of pain. Ultra-low-dose (ULD) opioid evokes hyperalgesia independently of analgesia. Tolerance to ULD-OIH develops with repeated dosing in rats.
The effects of ULD opioids were characterized in two distinct situations where hyperalgesia is expected to occur: following acute opioid treatment and after nerve injury.
First, ULD morphine was repeatedly administered (2x day for 5 days) by intrathecal (i.t., 0.01 microg) or intraperitoneal (i.p., 20 microg/kg) routes in rats. Second, morphine (0.01 microg i.t.; 20 microg/kg i.p.) was administered (2x day for 5 days) prior to acute morphine (30 microg i.t.; 10 mg/kg i.p). Third, ULD morphine (20 microg/kg/2x day, i.p.) was given either immediately after nerve injury (days 1-28) or when hyperalgesia was manifested (days 7-14). The tail-flick and paw-pressure tests were used in noninjured and nerve-injured rats, respectively.
Tolerance was developed to OIH with repeated ULD morphine by the i.p. route but not the i.t. route. Prior exposure to ULD morphine (i.p.) caused prolongation of morphine analgesia in intact rats and inhibition of the development (but not reversal) of hyperalgesia in nerve-injured rats. Abolishment of OIH (pain desensitization) may diminish activation of pain facilitatory systems due to nerve injury and opioid treatment.
Although the translational aspect of this preclinical study has limitations, the present data may suggest a new strategy for the pre-emptive use of ULD opioids to prevent the development of neuropathic pain with certain procedures or disease states.
除了产生镇痛作用外,阿片类药物还可增加人类和啮齿动物对疼痛的敏感性(阿片类药物诱导的痛觉过敏[OIH])。耐受性/ OIH可能由与神经损伤后(神经性疼痛)痛觉过敏发展相似的机制介导。OIH可能是阿片类药物疗效丧失和/或疼痛加剧的一个原因。超低剂量(ULD)阿片类药物可独立于镇痛作用诱发痛觉过敏。在大鼠中,重复给药会导致对ULD - OIH产生耐受性。
在预期会发生痛觉过敏的两种不同情况下,即急性阿片类药物治疗后和神经损伤后,对ULD阿片类药物的作用进行了表征。
首先,通过鞘内注射(i.t.,0.01微克)或腹腔注射(i.p.,20微克/千克)途径,在大鼠中重复给予ULD吗啡(每天2次,共5天)。其次,在给予急性吗啡(30微克i.t.;10毫克/千克i.p.)之前,先给予吗啡(0.01微克i.t.;20微克/千克i.p.)(每天2次,共5天)。第三,ULD吗啡(20微克/千克/每天2次,i.p.)在神经损伤后立即给予(第1 - 28天)或在痛觉过敏出现时给予(第7 - 14天)。分别在未受伤和神经损伤的大鼠中使用甩尾试验和 paw - pressure试验。
通过腹腔注射途径重复给予ULD吗啡可产生对OIH的耐受性,但鞘内注射途径则不会。预先暴露于ULD吗啡(腹腔注射)可使完整大鼠的吗啡镇痛作用延长,并抑制神经损伤大鼠痛觉过敏的发展(但不能逆转)。消除OIH(疼痛脱敏)可能会减少由于神经损伤和阿片类药物治疗导致的疼痛促进系统的激活。
尽管这项临床前研究的转化方面存在局限性,但目前的数据可能提示一种新的策略,即抢先使用ULD阿片类药物来预防某些手术或疾病状态下神经性疼痛的发展。